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Viral hemorrhagic fevers are associated with high
rates of illness and death. Although therapeutic options are
limited, early differential diagnosis has implications for con-
tainment and may aid in clinical management. We describe
a diagnostic system for rapid, multiplex polymerase chain
reaction identification of 10 different causes of viral hemor-
rhagic fevers. 
I
ncreasing international travel, trafficking in wildlife,
political instability, and terrorism have made emerging
infectious diseases a global concern. Viral hemorrhagic
fevers (VHF) warrant specific emphasis because of their
high rates of illness and death, and the potential for rapid
dissemination by human-to-human transmission. The term
“viral hemorrhagic fever” characterizes a severe multisys-
tem syndrome associated with fever, shock, and bleeding
diathesis caused by infection with any of several RNA
viruses, including Ebola virus and Marburg virus (MARV)
(family Filoviridae); Lassa virus (LASV) and the South
American hemorrhagic fever viruses Guanarito virus, Junín
virus, Machupo virus, and Sabiá virus (Arenaviridae); Rift
Valley fever virus (RVFV), Crimean-Congo hemorrhagic
fever virus (CCHFV), and hantaviruses (Bunyaviridae);
and Kyasanur Forest disease virus (KFDV), Omsk hemor-
rhagic fever virus, yellow fever virus (YFV), and dengue
viruses (Flaviviridae) (1,2). Although clinical management
of VHF is primarily supportive, early diagnosis is needed to
contain the contagion and implement public health meas-
ures, especially if agents are encountered out of their natu-
ral geographic context.
Vaccines have been developed for YFV, RVFV, Junín
virus, KFDV, and hantaviruses (3–7), but only YFV vac-
cine is widely available. Early treatment with immune plas-
ma was effective in Junín virus infection (8). The
nucleoside analog ribavirin may be helpful if given early in
the course of Lassa fever (9), Crimean-Congo hemorrhagic
fever (10), or hemorrhagic fever with renal syndrome (11)
and is recommended in postexposure prophylaxis and early
treatment of arenavirus and bunyavirus infections (12). 
Methods for direct detection of nucleic acids of micro-
bial pathogens in clinical specimens are rapid, sensitive,
and obviate the need for high-level biocontainment.
Numerous systems are described for nucleic acid detection
of VHF agents; however, none are multiplex (13).
Although geographic location or travel history of suspect-
ed patients usually restricts the number of agents to be con-
sidered, diagnosis of VHF may be difficult in case of an
intentional release (12). Symptoms of VHF are initially
nonspecific and may include fever, headache, myalgia, and
gastrointestinal or upper respiratory tract complaints (1);
thus, assays that allow simultaneous consideration of mul-
tiple agents are needed. 
We recently described the application of MassTag poly-
merase chain reaction (PCR) in the context of differential
diagnosis of respiratory disease (14). MassTag PCR is a
multiplex assay in which microbial gene targets are coded
by a library of 64 distinct mass tags. Nucleic acids (RNA
or DNA) are amplified by multiplex (reverse transcrip-
tion–) PCR using up to 64 primers, each labeled by a
photo-cleavable link with a different molecular weight tag.
After separation of the amplification products from unin-
corporated primers and release of the mass tags from the
amplicons by UV irradiation, tag identity is analyzed by
mass spectrometry. The identity of the microbe in the clin-
ical sample is determined by the presence of its 2 cognate
tags, 1 from each primer.
The Study
To facilitate rapid differential diagnosis of VHF agents,
we established the Greene MassTag Panel VHF version 1.0,
which comprises the following targets: Ebola Zaire virus
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RVFV, CCHFV, Hantaan virus (HNTV), Seoul virus
(SEOV), YFV, and KFDV. Oligonucleotide primers were
designed in conserved genomic regions to detect the broad-
est number of members for a given pathogen species. We
developed a software program that culls sequence informa-
tion from GenBank, performs multiple alignments with
ClustalW, and designs primers optimized for multiplex
PCR. The program uses a greedy algorithm to identify con-
served sequences and create the minimum set of primers for
amplification of all sequences in the alignment. Primers are
selected within standard design constraints whenever possi-
ble (melting temperature 55°C–65°C, guanine-cytosine
content 40%–60%, no hairpins); degenerate positions are
introduced in cases where template divergence requires
more flexibility. Although degeneracy is not tolerated in the
five 3′ nucleotides, MassTag PCR allows up to 4 nonneigh-
boring variable positions per primer. Primers are checked
by the basic local alignment search tool for potential
hybridization to sequenced vertebrate genomes (Table 1).
Because only released mass tags are analyzed, stagger-
ing the size of amplification products created in multiplex
reactions is unnecessary; thus, primers are selected for
efficient and consistent performance irrespective of ampli-
con size (typically 80–200 bp). Before committing to syn-
thesis of tagged primers, the functionality of candidate
multiplex primer panels is examined in a series of amplifi-
cation reactions that use prototype templates representing
individual microbial targets. Primers that fail to yield a sin-
gle, specific product band in agarose gel analysis are
replaced. Target sequence standards for evaluation are
cloned into pCR2.1-TOPO (Invitrogen, Carlsbad, CA,
USA) by using PCR amplification of cDNA templates
obtained by reverse transcription (RT) of extracts from
infected, cultured cells or by assembly of overlapping syn-
thetic polynucleotides.
The agents assayed in the VHF panel have RNA
genomes; thus, assay sensitivity was determined by using
synthetic RNA standards. Synthetic RNA standards were
generated from linearized target sequence plasmids by
using T7 polymerase (mMessage mMachine, Invitrogen).
After quantitation by UV spectrometry, RNA was serially
diluted in 2.5 µg/mL yeast tRNA (Sigma, St. Louis, MO,
USA), reverse transcribed with random hexamers by using
Superscript II (Invitrogen), and analyzed by MassTag PCR
as previously described (14). QIAquick 96 PCR purifica-
tion cartridges (Qiagen, Hilden, Germany, with modified
binding and wash buffers) were used to remove unincorpo-
rated primers before tags were decoupled from amplifica-
tion products by UV photolysis in a flow cell and analyzed
in a quadrapole mass spectrometer by using positive-mode
atmospheric pressure chemical ionization (APCI-MS,
Agilent Technologies, Palo Alto, CA, USA). The sensitivi-
ty of the 10-plex VHF panel with synthetic RNA standards
was <50 RNA copies per assay (Table 2). Sensitivity and
specificity of multiplex primer panels is assessed empirical-
ly by using calibrated synthetic standards as well as tissue
culture–derived viral nucleic acid for each assembled panel. 
Tissue culture extracts were used to examine assay
specificity. Random primed cDNA obtained from cultures
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Gambia and Côte d’Ivoire, RVFV, CCHFV, HTNV, SEOV,
and LASV strains Josiah, NL, and AV were subjected to
mass tag analysis. In all instances, only the appropriate
cognate mass tags were detected (data not shown). No spu-
rious signal was identified in assays with water or RNA
controls.
Performance with clinical materials was tested by using
blood, sera, or oral swabs from 24 human patients of VHF
previously diagnosed through virus isolation, RT-PCR, or
antigen detection enzyme-linked immunosorbent assay.
Differential diagnosis by blinded MassTag PCR analysis
was accurate in all cases (Table 3). For the samples from
the 2005 Angola Marburg outbreak the result of MassTag
PCR was similar to that of diagnostic single-plex PCR.
ZEBOV sample 5004, obtained on day 17 of illness when
serologic test results were positive for immunoglobulin M
(IgM) and IgG, was negative by viral culture but positive
in MassTag PCR.
Conclusions
These results confirm earlier work in respiratory dis-
eases that show that MassTag PCR offers a rapid, sensi-
tive, specific, and economic approach to differential
diagnosis of infectious diseases. Small, low-cost, or
mobile APCI-MS units extend the applicability of this
technique beyond selected reference laboratories. Given
the capacity of the method to code for up to 32 genetic tar-
gets, we are expanding the hemorrhagic fever panel to
include additional viruses (dengue and South American
hemorrhagic fever viruses) and are exploring the inclusion
of bacterial and parasitic agents that may result in similar
clinical signs and symptoms and, thus, have to be consid-
ered in differential diagnosis. 
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